Skip to content
Menu

Janux Therapeutics, Inc. JANX

Full chart Compare
Set alert

Price alert · JANX

All alert types
10.08 USD -0.21 (-2.04%)

Regular-session close

10.15 +0.07 +0.69%

After hours · Nov 20, 5:26 PM ET

10.05 Day range 10.54
10.08 52-week range 34.74
YTD
-26.96%
1 year
-64.74%

5D -1.59 (-12.64%)

1112TueWedThuFriMon10.99
Market cap
616.73M
Revenue (ttm)
23.29M
EPS (ttm)
-1.59
Shares out
61.14M
Forward P/E
-6.72
YTD return
-26.96%
1-year return
-64.74%
50-day average
17.52
200-day average
15.41
Volume
1.11M
Avg volume
952.26K
Open
10.16
Previous close
10.29
Day's range
10.05 – 10.54
52-week range
10.08 – 34.74
Analysts
Strong Buy
Price target
32.07 (+218.1%)
Earnings date
Feb 25, 2027

Key statistics

Enterprise value
57.27M
Price / sales
46.28
Price / book
1.18
Revenue growth
-7.10%
Free cash flow
-24.24M
Total cash
945.72M
Total debt
20.38M
Return on equity
-10.58%
Short % of float
11.15%

Fundamental scorecard

8 of 25 checks passed on JANX’s reported financials

ValueGrowthProfitabilityHealthDividend

8of 25 checks passed

  • Value 2 of 5
  • Growth 2 of 5
  • Profitability 1 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
JANX Revenue — quarterly 9.29M
JANX Net income — quarterly -21.57M
JANX EPS — quarterly -0.34

Earnings

JANX recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 25, 2027Dec 30, 2026-0.52———
Nov 5, 2026Sep 30, 2026-0.47345-0.34+0.13+28.19%
Aug 6, 2026Jun 30, 2026-0.2513-0.35-0.10-39.28%
May 7, 2026Mar 31, 2026-0.5202-0.39+0.13+25.03%
Feb 26, 2026Dec 31, 2025-0.65-0.51+0.14+21.54%
Nov 6, 2025Sep 30, 2025-0.60-0.39+0.21+35.00%

Upgrades / downgrades

JANX analyst upgrades and downgrades
DateFirmActionFromTo
Nov 6, 2026Truist SecuritiesmainBuyBuy
Nov 6, 2026WedbushmainOutperformOutperform
Nov 6, 2026BarclaysmainUnderweightUnderweight
Aug 24, 2026Wolfe ResearchupPeer PerformOutperform
Aug 7, 2026GuggenheimmainBuyBuy
May 8, 2026Piper SandlermainOverweightOverweight

About Janux Therapeutics, Inc.

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. It also develops JANX011, a CD19-targeted adaptive immune response modulator that is in phase 1 clinical study developed for autoimmune diseases. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates; and Bristol Myers Squibb to develop and commercialize an undisclosed, novel tumor-activated therapeutic targeting a validated solid tumor antigen expressed across several human cancer types. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
januxrx.com

News

Your note

Sign in to keep a note on JANX — it syncs with the Stock Master app.

Insider holders

JANX insider holders
InsiderRelationLatest transactionDateShares held
CAMPBELL DAVID ALANOfficer and DirectorStock GiftJul 30, 2026264,742
CAPPS VICKIE LYNNDirectorStock Award(Grant)Jun 10, 202679,598
DIRAIMONDO THOMAS PH.D.OfficerStock Award(Grant)Jan 1, 2026155,825
DOYLE JANEEN NOELOfficerSaleJun 1, 202675,941
GO WILLIAM M.D., PH.D.OfficerStock Award(Grant)Feb 1, 202644,000
GUJRATHI SHEILADirectorStock Award(Grant)Jun 10, 2025118,889

Institution ownership

JANX institution ownership
Holder% heldSharesValueReported
RA Capital Management, L.P.18.30%11,189,693197.27MJun 29, 2026
Blackrock Inc.10.03%6,134,667108.15MJun 29, 2026
Prosight Management, Lp6.22%3,804,48167.07MJun 29, 2026
State Street Corporation4.92%3,004,89952.98MJun 29, 2026
FMR, LLC3.95%2,412,82542.54MJun 29, 2026
Federated Hermes, Inc.3.85%2,352,92741.48MJun 29, 2026

Fund ownership

JANX fund ownership
Holder% heldSharesValueReported
Federated Hermes MDT Series-Federated Hermes MDT Small Cap Core Fund2.25%1,374,11524.23MJul 30, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.07%1,263,83722.28MJun 29, 2026
iShares Trust-iShares Russell 2000 ETF2.01%1,227,37321.64MSep 29, 2026
SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF1.86%1,134,39320.00MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund0.90%552,3689.74MJun 29, 2026
Fidelity Salem Street Trust-Fidelity Small Cap Index Fund0.77%471,4608.31MAug 30, 2026